TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: Tagamet
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
2020health's Blog 